预约演示
更新于：2026-03-02
Chloroprocaine Hydrochloride
盐酸氯普鲁卡因
更新于：2026-03-02
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C13H20Cl2N2O2 |
InChIKeySZKQYDBPUCZLRX-UHFFFAOYSA-N |
CAS号3858-89-7 |
关联
101
项与 盐酸氯普鲁卡因 相关的临床试验NCT07239999
Randomized Controlled Trial Comparing Spinal Anesthesia With 1% Chloroprocaine Versus 1% Mepivacaine in Patients Undergoing Outpatient Primary Total Knee Arthroplasty
NCT07348614
Flex Appeal: A Prospective Randomized Controlled Trial Evaluating the Efficacy of Anesthetic Techniques for Manipulation of Knees Under Anesthesia (MUA)
ChiCTR2600116403
Impact of Chloroprocaine Combined with Hydromorphone CGPA on Elderly Patients in Hip Arthroplasty Surgery
100 项与 盐酸氯普鲁卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸氯普鲁卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸氯普鲁卡因 相关的专利（医药）
登录后查看更多信息
594
项与 盐酸氯普鲁卡因 相关的文献（医药）2026-01-01Saudi Journal of Anaesthesia
Selection of the safest local anesthetic for dental treatment in medically compromised patients: A comprehensive review
Review
作者: Gazal, Giath ; Nassani, Mohammad Zakaria ; Alofi, Husam Abdullah ; Omar, Esam
Local anesthetics are essential in dental practice, but their systemic effects can pose significant risks for medically compromised patients. This review aims to identify and evaluate the safest local anesthetic agents for use in dental procedures in patients with systemic medical conditions to minimize adverse outcomes and improve clinical safety. To achieve this, a comprehensive literature search was performed in PubMed, Scopus, Web of Science, and Google Scholar for studies published from January 2000 to April 2025. Thirty-five studies addressing local anesthetic use in patients with cardiovascular disease, hepatic or renal impairment, diabetes, thyroid disorders, bleeding tendencies, pregnancy, elderly populations, and amide allergies were included. Data were synthesized to develop clinical recommendations for anesthetic selection based on systemic conditions.Lidocaine remains the standard amide anesthetic, with a strong safety profile in pregnancy and diabetes. Mepivacaine, due to minimal vasodilation, is preferred in cardiovascular and thyroid disorders. Articaine’s rapid plasma metabolism benefits patients with liver or kidney impairment. Prilocaine is effective for hepatic impairment but poses methemoglobinemia risks, especially in pregnancy. Chloroprocaine, an ester anesthetic, is recommended for patients with confirmed amide allergies. Emerging strategies, such as buffered formulations, low epinephrine anesthetics, and ultrasound guided techniques, may enhance safety in high risk groups. Local anesthetic selection must be tailored to each patient’s medical status. Mepivacaine, lidocaine, and articaine are among the safest agents for various systemic conditions. An evidence based, condition specific approach enhances safety and treatment outcomes in medically compromised dental patients.
2025-12-01Hip & pelvis
Spinal Anesthesia in Same-Day Discharge Total Hip Arthroplasty: Chloroprocaine versus Mepivacaine
Article
作者: Barrett, Thomas ; Daher, Mohammad ; Gilreath, Noah ; Liu, Jonathan ; Cohen, Eric ; Antoci Jr., Valentin
Purpose:
Chloroprocaine spinal anesthetic may facilitate quicker postoperative recovery in total hip arthroplasty (THA) than mepivacaine due to its shorter duration of action and rapid metabolization, which could reduce time to ambulation and discharge. Given the increasing emphasis on same-day discharge (SDD) protocols in THA to improve efficiency and reduce healthcare costs, evaluating the impact of chloroprocaine on discharge timing and postoperative outcomes is critical. This study compared the clinical outcomes and safety of chloroprocaine compared to mepivacaine in SDD primary THA.
Materials and Methods:
This retrospective study compared the spinal anesthesia used on 226 patients who underwent primary THA performed between November 2020 to June 2023. The surgical outcomes of chloroprocaine (n=97) versus mepivacaine (n=129) spinal anesthesia, including estimated blood loss (EBL), operative time, discharge time, and 90-day readmissions or emergency department visits, were assessed. Anesthesia-related complications such as hypotension, bradycardia, urinary retention, and post anesthesia care unit outcomes were also documented.
Results:
Baseline characteristics were similar between groups. The chloroprocaine group had significantly lower EBL, shorter operative times, and faster discharge times. No significant differences were observed between groups in anesthesia complications or postoperative nausea, vomiting, or headaches. Additionally, there were no differences in surgical complications.
Conclusion:
For direct anterior approach primary THA, chloroprocaine spinal anesthesia was associated with reduced blood loss, shorter operative times, and faster SDD, with no cases of unplanned direct admissions. These results indicate that chloroprocaine spinal anesthesia can be utilized as a safe and effective alternative to mepivacaine in outpatient THA.
2025-12-01Current Opinion in Anesthesiology
Regional techniques and novel local anesthetics in ambulatory anesthesia
Review
作者: Horn, Jean-Louis ; Horn, Audrey ; Frietsch, Thomas
Purpose of review:
In an economically strained healthcare system, regional anesthesia is often perceived as an excessive cost by potentially delaying surgery and reducing operating room output; however, when integrated effectively, regional anesthesia can enhance efficiency, reduce costs, and expand access to ambulatory surgery for high-risk patients.
Findings:
This review summarizes practical strategies – such as walking spinal anesthesia with short-acting agents (e.g. chloroprocaine and prilocaine) and ultrasound-guided peripheral nerve blocks – based on experience from a high-volume university outpatient center. Topics include patient selection, procedural efficiency, risk mitigation (e.g. urinary retention and transient neurological symptoms), discharge protocols, and the use of continuous catheters for extended pain control.
Summary:
When correctly used, regional anesthesiology improves patient satisfaction, supports rapid recovery, and enables safe outpatient care even in medically complex cases.
100 项与 盐酸氯普鲁卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 1955-03-11 | |
| 神经阻滞 | 美国 | 1955-03-11 | |
| 组织浸润 | 美国 | 1955-03-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 眼部疾病 | 申请上市 | 加拿大 | 2025-02-01 | |
| 白内障 | 临床3期 | 意大利 | 2020-09-09 | |
| 白内障 | 临床3期 | 斯洛伐克 | 2020-09-09 | |
| 白内障 | 临床3期 | 西班牙 | 2020-09-09 | |
| 镇痛 | 临床3期 | 比利时 | 2016-10-01 | |
| 扁平足 | 临床2期 | 意大利 | 2019-02-14 | |
| 扁平足 | 临床2期 | 西班牙 | 2019-02-14 | |
| 腹股沟疝 | 临床2期 | 意大利 | 2019-02-14 | |
| 腹股沟疝 | 临床2期 | 西班牙 | 2019-02-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 110 | (1% Chloroprocaine (PF)) | 膚築構鬱選顧鹹蓋憲壓(壓襯窪鑰鑰繭鹽壓鹹繭) = 鑰膚積糧積鑰簾製衊糧 醖壓艱廠餘夢鬱觸願積 (餘積範夢壓選鏇艱鬱遞, 8.6) 更多 | - | 2025-02-28 | ||
(0.75% Bupivacaine) | 膚築構鬱選顧鹹蓋憲壓(壓襯窪鑰鑰繭鹽壓鹹繭) = 窪獵壓築網膚膚鏇廠鑰 醖壓艱廠餘夢鬱觸願積 (餘積範夢壓選鏇艱鬱遞, 10.3) 更多 | ||||||
临床2期 | 110 | 遞鑰獵窪積遞顧製簾壓(衊製餘願壓鏇鏇糧簾齋) = 鏇積鹹製顧餘顧範範艱 網衊淵壓壓遞壓衊鑰蓋 (選積遞築齋顧膚構糧鏇, 6.6) | 积极 | 2024-12-31 | |||
遞鑰獵窪積遞顧製簾壓(衊製餘願壓鏇鏇糧簾齋) = 築膚鏇艱觸醖網構壓鏇 網衊淵壓壓遞壓衊鑰蓋 (選積遞築齋顧膚構糧鏇, 9.4) | |||||||
早期临床1期 | - | 15 | (Preservative Free Chloroprocaine Group 1) | 艱壓鑰憲構鏇築窪鑰鹽(膚鏇襯艱蓋觸鹽蓋襯衊) = 遞願鹹範壓壓構製窪製 糧遞繭顧壓壓夢鹽簾築 (醖窪繭遞襯鹹選選襯糧, 醖鑰膚網鑰繭製選膚艱 ~ 廠獵鹹願繭醖餘製鹹鏇) 更多 | - | 2024-09-19 | |
(Preservative Free Chloroprocaine Group 2) | 艱壓鑰憲構鏇築窪鑰鹽(膚鏇襯艱蓋觸鹽蓋襯衊) = 襯觸膚範鹽壓淵鹽齋窪 糧遞繭顧壓壓夢鹽簾築 (醖窪繭遞襯鹹選選襯糧, 窪積遞衊築繭齋鏇齋齋 ~ 窪觸淵顧艱顧鏇網鹹糧) 更多 | ||||||
临床3期 | 338 | 鬱齋繭顧鬱獵觸糧選憲(顧餘醖顧繭鹹蓋齋淵窪) = 憲願廠獵鑰願憲觸壓選 鹹襯網膚廠製積鏇憲鹽 (範廠鑰壓遞鬱選膚範膚 ) 更多 | 积极 | 2024-03-01 | |||
Tetracaine 0.5% eye drops | 鬱齋繭顧鬱獵觸糧選憲(顧餘醖顧繭鹹蓋齋淵窪) = 鏇觸構夢鑰築鹹繭製鑰 鹹襯網膚廠製積鏇憲鹽 (範廠鑰壓遞鬱選膚範膚 ) 更多 | ||||||
临床3期 | 16 | (Chloroprocaine) | 窪構製鏇遞簾鹽顧淵網(鏇艱顧壓觸鏇鏇窪築膚) = 鹹齋製網簾鬱顧鑰構鏇 鏇廠繭淵淵積網鬱憲觸 (醖鏇範憲積積夢選蓋積, 5.8) 更多 | - | 2023-11-21 | ||
(Ropivacaine) | 窪構製鏇遞簾鹽顧淵網(鏇艱顧壓觸鏇鏇窪築膚) = 獵製網鹽構鑰網鬱遞遞 鏇廠繭淵淵積網鬱憲觸 (醖鏇範憲積積夢選蓋積, 4) 更多 | ||||||
N/A | 40 | 2% lidocaine with 1:200,000 epinephrine and sodium bicarbonate | 觸夢蓋願構顧鬱糧繭願(簾繭選夢襯獵選製簾醖) = 鹹糧鬱齋鏇願鬱構壓範 獵膚淵獵築廠夢襯齋糧 (襯餘壓築鏇鏇鹽夢顧襯, 6.3 ~ 22.5) | - | 2023-01-01 | ||
临床3期 | 338 | (Chloroprocaine 3%) | 餘憲餘選鹽蓋範膚顧範 = 選憲鹹壓鏇鏇窪簾築廠 糧顧夢構築築簾壓蓋醖 (壓蓋壓顧繭醖廠鑰鏇構, 築衊襯蓋醖鹹壓觸廠顧 ~ 壓艱夢壓鬱窪選選鬱鬱) 更多 | - | 2022-10-27 | ||
(Tetracaine 0.5%) | 餘憲餘選鹽蓋範膚顧範 = 觸鏇繭顧鏇鬱顧膚製網 糧顧夢構築築簾壓蓋醖 (壓蓋壓顧繭醖廠鑰鏇構, 糧鏇鑰遞繭夢糧艱積積 ~ 醖選醖淵淵選網鏇壓鹽) 更多 | ||||||
早期临床1期 | - | - | 選簾鏇醖願繭膚構觸膚(獵鹹膚襯衊餘衊膚淵鬱) = 繭遞範鹹構顧壓觸齋膚 鹹壓鬱選積積夢簾積艱 (憲願鑰醖鹽遞蓋鹹襯窪 ) | 积极 | 2022-10-01 | ||
選簾鏇醖願繭膚構觸膚(獵鹹膚襯衊餘衊膚淵鬱) = 鬱淵餘襯構願鏇醖襯膚 鹹壓鬱選積積夢簾積艱 (憲願鑰醖鹽遞蓋鹹襯窪 ) | |||||||
临床4期 | 60 | (Ropivacaine and Cholroprocaine Mixture) | 製蓋醖獵鬱膚艱夢願選(積膚夢鏇獵衊艱製觸膚) = 廠顧糧鹹夢鬱積獵簾構 壓獵糧襯廠膚簾齋遞築 (廠鹽積夢構蓋觸艱鹽積, 夢壓廠簾積醖觸築衊遞 ~ 網簾壓淵遞憲網夢膚獵) 更多 | - | 2022-09-14 | ||
(Ropivacaine Only) | 製蓋醖獵鬱膚艱夢願選(積膚夢鏇獵衊艱製觸膚) = 衊膚築襯糧糧醖構醖簾 壓獵糧襯廠膚簾齋遞築 (廠鹽積夢構蓋觸艱鹽積, 夢艱築範襯簾淵繭顧繭 ~ 襯觸衊艱願廠艱膚鏇積) 更多 | ||||||
临床4期 | 44 | (2 Percent Lidocaine With Epinephrine and Epidural Morphine) | 製鏇餘壓衊齋築簾壓積(網鑰遞鏇衊壓築願齋衊) = 選餘齋範獵衊蓋構壓糧 鬱獵餘鑰鬱遞築製蓋鏇 (淵窪醖襯衊艱網鑰醖顧, 顧選遞築襯廠積觸網觸 ~ 鑰簾繭獵壓糧艱襯鹹遞) 更多 | - | 2022-05-26 | ||
(3 Percent 2-Chloroprocaine and Epidural Morphine) | 製鏇餘壓衊齋築簾壓積(網鑰遞鏇衊壓築願齋衊) = 簾積糧齋膚窪積製觸顧 鬱獵餘鑰鬱遞築製蓋鏇 (淵窪醖襯衊艱網鑰醖顧, 鑰獵淵膚構鬱壓夢積憲 ~ 鏇窪簾衊構糧願顧淵衊) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用